rasagiline / Generic mfg. - LARVOL DELTA

Nocturnal Hypokinesia and Early Morning OFF in Parkinson's Disease: State-of-the-Art and Systematic Review of Treatment Availability. (PubMed, Curr Neurol Neurosci Rep) - "Pharmacologic treatments include standard and sustained-release levodopa, dopamine agonists (rotigotine, ropinirol, pramipexole, and apomorphine), MAO-B inhibitors (rasagiline, safinamide), COMT inhibitors (opicapone), and rescue therapies like inhaled or dispersible levodopa or apomorphine injection. For mild, disturbing symptoms in early PD, inhaled or dispersible levodopa or apomorphine injection are advised. In moderate to advanced stages, treatment options include long-acting dopamine agonists, MAO-B inhibitors, sustained-release levodopa, or COMT inhibitors selected based on factors such as daytime motor symptoms, and non-motor symptoms."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review. (PubMed, Front Neurol) - "Currently available therapeutic options for PD-related fatigue are limited, with rasagiline considered only "possibly useful," and most other pharmacologic and non-pharmacological strategies lacking rigorous evidence...It examines the clinical and neurobiological intersections between fatigue and neuropsychiatric symptoms in PD, highlighting key diagnostic challenges, treatment limitations, and future directions. Standardizing terminology, dissecting fatigue from overlapping neuropsychiatric symptoms, identifying reliable biomarkers, and conducting well-designed, mechanism-based clinical trials are essential next steps to redefine fatigue as a measurable and treatable symptom in PD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Fatigue • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Effects of MAO-B and COMT inhibitors on sleep disturbances in Parkinson's disease: A network meta-analysis. (PubMed, J Mov Disord) - "However, in analyses of objective PSG data, safinamide was found to significantly increase REM sleep duration (mean difference, 5.70 [95% CI, 2.26, 9.14]) and decrease wake time after sleep onset (mean difference, -10.20 [-19.38, -1.02]) compared to rasagiline and placebo. Given the limited number and small scale of available trials, the overall evidence should be interpreted cautiously. Nonetheless, this analysis highlights the need for further high-quality trials focused on sleep outcomes to guide personalized use of MAO-B and COMT inhibitors for sleep disturbances in PD."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

Interaction between rasagiline and Pueraria radix in in vitro models of parkinson's disease. (PubMed, BMC Complement Med Ther) - "These findings suggest that the RASA - PR combination offers enhanced therapeutic potential through synergistic effects, while maintaining favourable metabolic compatibility. This study establishes a scientific foundation for integrating traditional herbal medicine with conventional pharmaceuticals in PD management, potentially allowing for reduced conventional drug dosages while improving therapeutic outcomes."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson's Disease: A Case Report (MDS Congress 2025) - "Prior treatments—including Sinemet, Rotigotine, Ropinirole, Clonazepam, Amantadine, and Rasagiline—were ineffective and caused additional symptoms like tremors and fatigue. To date, no published case studies have demonstrated significant improvement in a patient's freezing of gait (FoG) with trihexyphenidyl (Artane), except for a single case reported in 2020 (1). That study described a patient with a FoG-like gait disturbance characterized by direction-associated FoG occurring exclusively during forward walking, who experienced gait improvement with trihexyphenidyl. However, the patient's leg symptoms were more consistent with task-specific dystonia, as subsequent surface electromyography (EMG) studies revealed dystonic co-contraction in the leg during forward walking in the OFF-state, but not during backward walking or side-stepping, supporting a diagnosis of task-specific dystonia."

Case report • Clinical • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson's Disease (MDS Congress 2025) - "Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment stability and demographic influences. No single add-on therapy demonstrated superior stability, highlighting comparable efficacy across options. Sex significantly influenced therapy adjustments, with females requiring more frequent modifications. These findings underscore the importance of personalized treatment strategies in fluctuating PD management."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson's Disease (MDS Congress 2025) - " Among 44 sporadic PD cases, 21 received MAOBIs (selegiline: 13, rasagiline: 8), 18 received levodopa, and 5 received dopamine agonists. Patients with less orthostatic hypotension and preserved postganglionic cardiac sympathetic function were more likely to benefit from MAOBIs. Their MAO-A inhibitory effect may suppress norepinephrine metabolism, enhancing motor function via dopamine activation. Therefore, PD patients with mild orthostatic hypotension and mild MIBG myocardial scintigraphy abnormalities, where endogenous norepinephrine is retained, may experience greater motor symptom improvement with MAOBIs."

CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Deep Brain Stimulation (DBS) Placement in a Patient with Parkinson's disease (PD) and Polyostotic Fibrous Dysplasia (PFD) (MDS Congress 2025) - "Multiple medications in his regimen were rasagiline, levodopa (immediate and controlled release), pramipexole and entacapone. DBS candidates with PD and a history of PFD can be evaluated, implanted and programmed."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Falls in Parkinson Disease, Videonystagmography and Fear of Falls – an Exploratory Study. (MDS Congress 2025) - "He was using levodopa, rasagiline and entacapone and was a candidate for DBS implantation. Even though both patients were independent on activities of daily living and had no significant impairment due to falls, they had high fear of falling and videonystagmography findings showing saccadic abnormalities. These findings may be related to a higher risk of falling in the near feature, which may have an impact on patients' prognosis and decision-making regarding continuous dopaminergic therapeutic strategies, but further investigation is needed to clarify if association exists."

CNS Disorders • Movement Disorders • Parkinson's Disease

Challenges in the diagnosis of the dementia spectrum: a case of behavioral variant frontotemporal dementia with idiopathic parkinson's disease (ECNP 2025) - "A 66-year-old university-educated woman with idiopathic Parkinson's disease, currently treated with rasagiline, presented with verbal expression difficulties, balance problems, disrupted sleep, and hand tremor... This case report emphasizes the importance of distinguishing Frontotemporal Dementia (FTD) from other neurodegenerative diseases.It highlights the need to consider FTD in the differential diagnosis of elderly patients exhibiting personality changes. Frontotemporal Dementia and Parkinsonism linked to chromosome 17 (FTDP-17) has also been suggested as distinct disorder. Although this patient did not have a family history, FTDP-17 can be considered."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Parkinson's Disease • Psychiatry • Sleep Disorder • MAPT

Neuroprotective effects of chemical constituents from Nicotiana tabacum L. in Parkinson's disease. (PubMed, Nat Prod Bioprospect) - "Systematic evaluation revealed three synergistic neuroprotective mechanisms: (1) Antioxidant activity: Scopoletin (3) and isoferulic acid (6) showed significant radical scavenging capacity (ABTS assay; IC50 = 27.74, and 18.13 μM, respectively); (2) Neuronal protection: cis-11,14,17-Eicosatrienoic acid methyl ester (14) enhanced survival (93.94% vs. control) in 6-OHDA-induced PC12 cells, surpassing rasagiline (88.36% at equivalent concentrations); (3) MAO-B inhibition: five compounds displayed selective inhibition, with scopoletin (3) exhibiting highest potency (Ki = 20.7 μM). Notably, plant prostaglandins (10/11) were identified as competitive MAO-B inhibitors first time through molecular docking and 100-ns MD simulations, revealing stable binding at the FAD site (ΔG = - 10.42, and - 9.75 kcal/mol, respectively)."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Antiparkinsonian Activity of Benzenesulfonamide Derivatives, Selective MAO-B Inhibitors. (PubMed, Bull Exp Biol Med) - "Rasagiline was used as the reference drug. Only compound S13 was comparable to rasagiline in preventing the development of rigidity and hypokinesia in animals and surpassed the reference drug in correcting emotional and behavioral activity."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. (PubMed, Pharmacol Res Perspect) - "Therefore, this study evaluates the effects of the irreversible MAO-B inhibitor selegiline and rasagiline and their combinations with conventional therapies on androgen-insensitive (PC-3, DU145) and androgen-sensitive (22Rv1, LNCaP, VCaP) PAC cell lines...Combination with enzalutamide in 22Rv1, and with docetaxel in PC-3 demonstrated potentiating and additive effects, respectively. Selegiline reduced FOXA1 and GLUT1 mRNA expressions related to cancer progression and metabolism in both cell lines, increased the apoptosis-related BAX in PC-3, and decreased AR, EGFR, and SNAI2 in 22Rv1 linked to proliferation and metastasis. These findings suggest potential for selegiline repurposing in both androgen-sensitive and -insensitive PAC therapy by promoting apoptosis and inhibiting cancer growth and survival signals, respectively."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • EGFR • FOXA1 • SLC2A1 • SNAI2

Add-on therapies to levodopa improve pain modulation in Parkinson's disease with motor fluctuations: A prospective cohort study. (PubMed, Parkinsonism Relat Disord) - "Pain processing is altered in pwPD, independently of subjective pain complaints. MAO-B inhibitors, particularly safinamide and rasagiline, appear to restore pain thresholds and improve QOL, supporting their role in managing pain in PD."

Journal • CNS Disorders • Fatigue • Mood Disorders • Movement Disorders • Pain • Parkinson's Disease • Psychiatry • COMT

Long-term effectiveness of safinamide vs. rasagiline in Parkinson's disease: A real-world retrospective study (EAN 2025) - "Safinamide may offer a better treatment option for PD patients, with higher persistence rates, better comorbidity management, stabilized levodopa dosage, and reduced use of additional medications compared to rasagiline."

Real-world • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Rasagiline Inhibits Human Melanoma Cell Viability and Interacts Synergistically with Mitoxantrone and Antagonistically with Cisplatin-In Vitro Isobolographic Studies. (PubMed, Cancers (Basel)) - " The anti-proliferative effects of carbidopa and rasagiline on four human malignant melanoma cell lines (A375, SK-MEL28, FM55P and FM55M2) were determined in MTT assay. Rasagiline combined with MTX exerted the most desirable synergistic interactions in relation to the anti-proliferative effects in four malignant melanoma cell lines, as assessed isobolographically. In contrast, rasagiline should not be combined with CDDP during the treatment of malignant melanoma due to the antagonistic interactions in the MTT assay."

Journal • Preclinical • CNS Disorders • Melanoma • Movement Disorders • Oncology • Parkinson's Disease • Solid Tumor

Enantioselective Gram-Scale Synthesis of Rasagiline via Chiral Phosphoric Acid-Catalyzed Reduction of Cyclic Imine. (PubMed, Chem Asian J) - "Furthermore, this approach showed broad substrate compatibility, underscoring its general utility in the asymmetric reduction of cyclic imine derivatives. Our strategy offers a practical and scalable alternative to existing methods for the synthesis of rasagiline and structurally related optically active amines."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Flecainide mediated sodium channel blockade enhances blood brain barrier integrity and promotes neuroprotection in neuroinflammation. (PubMed, Sci Rep) - "To evaluate the effects and understand the action mechanism of NaV blockers and MAO-B inhibitors (rasagiline, safinamide, flecainide and phenytoin) in neurological conditions, various techniques were used, including optical coherence tomography (OCT), optomotor response measurement (OMR), flow cytometry, histological evaluations, Evans blue assay, blood-brain barrier (BBB) permeability assay, western blot, proliferations assay, and gene expression analyses. The findings demonstrate induced neuroprotection and reduced disease progression, suggesting a novel therapeutic approach. Crucially, it reveals for the first time that NaV 1.5 channel blockade leads to neuroprotection primarily by affecting the BBB, a key factor in controlling immune cell migration, thus addressing a critical aspect of neuroinflammation."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review. (PubMed, J Comp Eff Res) - "Limitations include reliance on clinical trial data and Spanish cost models. Future research incorporating real-world evidence is warranted."

Clinical • HEOR • Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: New York Medical College

New P4 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A prospective,multicenter rasagiline pharmacogenomics study on Parkinson's disease (ChiCTR) - P4 | N=600 | Recruiting | Sponsor: Second Affiliated Hospital,School of Medicine,Zhejiang University; Second Affiliated Hospital,School of Medicine,Zhejiang University

Biomarker • New P4 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Rasagiline mesylate-based microneedle patches: A patient-friendly treatment regimen for Parkinson's disease. (PubMed, Int J Pharm) - "HMNs delivered 6.44 mg and 18.32 mg of RM at 6 h and 24 h, corresponding to ∼ 20 % and ∼ 60 % delivery, respectively. These findings highlight the potential of microneedles as a viable transdermal RM delivery system, offering an alternative to oral administration, while maintaining controlled drug release and stability."

Journal • CNS Disorders • Inflammatory Arthritis • Movement Disorders • Parkinson's Disease

Streamlined analytical strategy using resonance Rayleigh scattering signal amplification for nanoscale quantification of rasagiline in tablets with content assessment. (PubMed, BMC Chem) - "The utilization of existing RRS innovation to assess the target drug was extend to estimate content homogeneity was an impressive accomplishment. Clinical trial number: Not applicable."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Investigating the Inhibitory Potential of Halogenated Quinoline Derivatives against MAO‑A and MAO-B: Synthesis, Crystal Structure, Density Functional Theory, and Molecular Dynamics Simulations. (PubMed, ACS Omega) - "Docking studies revealed that Q3Cl4F and Q4F exhibit superior binding affinities compared to reference drugs, with Q3Cl4F demonstrating a binding score of -7.24 kcal/mol for MAO-A and -8.37 kcal/mol for MAO-B, outperforming harmine (-6.57 kcal/mol) and rasagiline (-6.47 kcal/mol)...Compound Q4F was observed to be more chemically reactive and less stable due to its lower energy band gap (ΔE) relative to that of Q3Cl4F. The influence of solvation was quantified, showing that aqueous environment enhances molecular stability and reduces reactivity."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative efficacy and safety of irreversible (rasagiline) and reversible (safinamide) monoamine oxidase inhibitors as add-on therapy for Parkinson's disease. (PubMed, J Neurol) - "Safinamide (100 mg) has good efficacy outcomes, whereas safinamide (50 mg) has favorable safety outcomes as compared to rasagiline for add-on therapy for PD."

Clinical • Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease